Merck re-commits to innovative infectious disease medicines
This re-commitment will take place during the Saturday through Tuesday conference where researchers will present over 30 selections of scientific data about investigational and marketed anti-infective medicines and Merck’s broad portfolio.
It has been an impressive year for Merck so far. On January 21, Merck acquired Cubist Pharmaceuticals Inc., and the companies have agreed to collaborate on their work concerning infectious diseases -- including antimicrobial research -- which is a focus for both companies. Merck’s programs cover a wide range of infectious diseases, beginning with discovery and ending with late-stage development. Some of the programs seek to develop vaccines, HIV and HCV medicines, and antibiotic and antifungal medicines.
“The rise in infections that are resistant to current antibiotics has become one of the world’s most pressing public health problems,” Merck executive vice president for strategic communications, global public policy and population health Julie Gerberding said. “We at Merck are proud to reaffirm our long-standing commitment to develop new therapeutics to fight infectious diseases, and to continue to collaborate with others to support antimicrobial stewardship to help slow the rate of emerging resistance.”